PLG0206
Prosthetic Joint Infection (PJI)
Phase 2/3Active
Key Facts
About Peptilogics
Peptilogics is a private, clinical-stage biotechnology company pioneering a new class of anti-biofilm therapeutics to address devastating medical device-related infections. Its lead candidate, PLG0206, is an engineered peptide with Orphan Drug, Fast Track, and QIDP designations, currently enrolling a pivotal Phase 2/3 trial (RETAIN) for prosthetic joint infections (PJI), where no approved therapies exist. The company leverages a proprietary platform for peptide engineering to target biofilm-forming pathogens, positioning itself in a large, underserved market with high clinical and economic burden. Leadership includes a mix of scientific founders and seasoned drug development executives.
View full company profileTherapeutic Areas
Other Prosthetic Joint Infection (PJI) Drugs
| Drug | Company | Phase |
|---|---|---|
| OsteoFloxacin™ | BioVinc | Pre-clinical |